Abstract
A multicentre, randomised, double-blind, placebo controlled, parallel group study to investigate the efficacy and tolerability of leucomax® (molgramostim; rHu GM-CSF) in conjunction with combination chemotherapy in the treatment of intermediate / poor prognosis patients with small cell lung cancer (SCLC) : R. Milroy 1, C. Cameron, K. McGregor, S.R. Bicknell, A. Dorward, on behalf of the West of Scotland Lung
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
